PFM Health Sciences LP reduced its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 26.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 810,400 shares of the company’s stock after selling 284,200 shares during the quarter. AstraZeneca accounts for about 1.2% of PFM Health Sciences LP’s holdings, making the stock its 28th biggest position. PFM Health Sciences LP’s holdings in AstraZeneca were worth $40,293,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also modified their holdings of AZN. Concord Wealth Partners purchased a new position in AstraZeneca during the fourth quarter worth about $34,000. IronBridge Private Wealth LLC purchased a new position in AstraZeneca during the fourth quarter worth about $35,000. Jackson Grant Investment Advisers Inc. purchased a new position in AstraZeneca during the fourth quarter worth about $38,000. SOA Wealth Advisors LLC. purchased a new position in AstraZeneca during the fourth quarter worth about $38,000. Finally, Atlas Private Wealth Advisors boosted its holdings in AstraZeneca by 117.3% during the first quarter. Atlas Private Wealth Advisors now owns 754 shares of the company’s stock worth $38,000 after purchasing an additional 407 shares during the last quarter. Hedge funds and other institutional investors own 15.63% of the company’s stock.
Shares of NASDAQ AZN traded up $0.32 during midday trading on Thursday, hitting $58.09. The company’s stock had a trading volume of 924,573 shares, compared to its average volume of 13,821,776. The company’s fifty day simple moving average is $57.99. AstraZeneca PLC has a one year low of $46.48 and a one year high of $60.93. The company has a quick ratio of 0.67, a current ratio of 0.87 and a debt-to-equity ratio of 1.21. The stock has a market cap of $152.46 billion, a price-to-earnings ratio of 38.01, a price-to-earnings-growth ratio of 1.18 and a beta of 0.56.
Several analysts have commented on AZN shares. Argus reaffirmed a “hold” rating on shares of AstraZeneca in a research report on Monday, April 19th. UBS Group reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Thursday, June 17th. Citigroup reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Wednesday. Finally, SVB Leerink lowered their price objective on shares of AstraZeneca from $64.00 to $63.00 and set an “outperform” rating on the stock in a research report on Friday, July 16th. One analyst has rated the stock with a sell rating, three have given a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $99.00.
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases.
Recommended Story: Why are gap-down stocks important?
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.